N. I. Pirogov Russian National Medical University, Russian Federal Ministry of Health, 117997 Moscow, Russia
Federal State Institution V. P. Serbsky Federal Medical Research Center of Psychiatry and Narcology National Scientific Research Center on Addictions of the Ministry of Healthcare of the Russian Federation, 119002 Moscow, Russia
Cells. 2019 Aug 9;8(8):863. doi: 10.3390/cells8080863.
Glioblastoma multiforme is the most aggressive malignant tumor of the central nervous system. Due to the absence of effective pharmacological and surgical treatments, the identification of early diagnostic and prognostic biomarkers is of key importance to improve the survival rate of patients and to develop new personalized treatments. On these bases, the aim of this review article is to summarize the current knowledge regarding the application of molecular biology and proteomics techniques for the identification of novel biomarkers through the analysis of different biological samples obtained from glioblastoma patients, including DNA, microRNAs, proteins, small molecules, circulating tumor cells, extracellular vesicles, etc. Both benefits and pitfalls of molecular biology and proteomics analyses are discussed, including the different mass spectrometry-based analytical techniques, highlighting how these investigation strategies are powerful tools to study the biology of glioblastoma, as well as to develop advanced methods for the management of this pathology.
多形性胶质母细胞瘤是中枢神经系统中最具侵袭性的恶性肿瘤。由于缺乏有效的药物和手术治疗，因此确定早期诊断和预后生物标志物对于提高患者的生存率和开发新的个性化治疗方法至关重要。基于此，本文综述了分子生物学和蛋白质组学技术在通过分析从胶质母细胞瘤患者获得的不同生物样本（包括 DNA、microRNAs、蛋白质、小分子、循环肿瘤细胞、细胞外囊泡等）中鉴定新型生物标志物方面的应用，总结了目前的相关知识。本文讨论了分子生物学和蛋白质组学分析的优缺点，包括不同的基于质谱的分析技术，并强调了这些研究策略是研究胶质母细胞瘤生物学以及开发该病理学管理的先进方法的有力工具。
